Sowell Financial Services LLC Has $9.51 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Sowell Financial Services LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,696 shares of the company’s stock after selling 1,011 shares during the quarter. Sowell Financial Services LLC’s holdings in Johnson & Johnson were worth $9,514,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. DORCHESTER WEALTH MANAGEMENT Co grew its stake in Johnson & Johnson by 0.6% in the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after purchasing an additional 414 shares in the last quarter. OneAscent Financial Services LLC grew its stake in Johnson & Johnson by 82.8% in the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after purchasing an additional 4,457 shares in the last quarter. TrueMark Investments LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $1,458,000. RAM Investment Partners LLC grew its stake in Johnson & Johnson by 4.5% in the fourth quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock valued at $265,000 after purchasing an additional 73 shares in the last quarter. Finally, RFG Advisory LLC grew its stake in Johnson & Johnson by 12.6% in the third quarter. RFG Advisory LLC now owns 18,758 shares of the company’s stock valued at $2,921,000 after purchasing an additional 2,102 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Morgan Stanley reduced their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Raymond James boosted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Finally, Wells Fargo & Company cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $177.31.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 1.4 %

JNJ stock opened at $150.19 on Thursday. Johnson & Johnson has a 1-year low of $144.95 and a 1-year high of $175.97. The firm has a market cap of $361.92 billion, a P/E ratio of 10.88, a P/E/G ratio of 2.55 and a beta of 0.53. The business’s 50 day moving average is $157.61 and its 200-day moving average is $156.14. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period in the prior year, the company posted $2.35 EPS. The company’s revenue was down 9.7% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.